Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 13
1946 126
1947 57
1948 34
1949 43
1950 40
1951 41
1952 86
1953 68
1954 92
1955 115
1956 69
1957 49
1958 35
1959 43
1960 63
1961 62
1962 112
1963 176
1964 192
1965 179
1966 200
1967 255
1968 292
1969 266
1970 218
1971 261
1972 256
1973 226
1974 243
1975 116
1976 106
1977 95
1978 97
1979 101
1980 89
1981 100
1982 106
1983 159
1984 207
1985 310
1986 410
1987 296
1988 284
1989 197
1990 152
1991 176
1992 194
1993 240
1994 230
1995 278
1996 238
1997 264
1998 266
1999 330
2000 390
2001 486
2002 447
2003 521
2004 639
2005 722
2006 797
2007 872
2008 970
2009 937
2010 1024
2011 1113
2012 1161
2013 1187
2014 1021
2015 1029
2016 848
2017 915
2018 952
2019 998
2020 1072
2021 1213
2022 959
2023 477
2024 1187
2025 755

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29,043 results

Results by year

Filters applied: . Clear all
Page 1
Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.
Lu JC, Wu LL, Sun YN, Huang XY, Gao C, Guo XJ, Zeng HY, Qu XD, Chen Y, Wu D, Pei YZ, Meng XL, Zheng YM, Liang C, Zhang PF, Cai JB, Ding ZB, Yang GH, Ren N, Huang C, Wang XY, Gao Q, Sun QM, Shi YH, Qiu SJ, Ke AW, Shi GM, Zhou J, Sun YD, Fan J. Lu JC, et al. Nat Commun. 2024 Jan 20;15(1):621. doi: 10.1038/s41467-024-44795-1. Nat Commun. 2024. PMID: 38245530 Free PMC article.
Vimseltinib: First Approval.
Lee A. Lee A. Drugs. 2025 Jul;85(7):985-989. doi: 10.1007/s40265-025-02191-z. Epub 2025 May 26. Drugs. 2025. PMID: 40415163 Review.
First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial.
Sha H, Tong F, Ni J, Sun Y, Zhu Y, Qi L, Li X, Li W, Yang Y, Gu Q, Zhang X, Wang X, Zhu C, Chen D, Liu B, Du J. Sha H, et al. Signal Transduct Target Ther. 2024 Jun 7;9(1):143. doi: 10.1038/s41392-024-01857-6. Signal Transduct Target Ther. 2024. PMID: 38844468 Free PMC article. Clinical Trial.
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy.
Hu D, Lyu X, Li Z, Ekambaram P, Dongre A, Freeman T, Joy M, Atkinson JM, Brown DD, Cai Z, Carleton NM, Crentsil HE, Little J 4th, Kemp F, Klei LR, Beecher M, Sperinde J, Huang W, Joensuu H, Srinivasan A, Pogue-Geile KL, Wang Y, Feng H, Eli LD, Lalani AS, Zou J, Tseng GC, Bruno TC, Lee AV, Oesterreich S, Wolmark N, Allegra CJ, Jacobs SA, McAllister-Lucas LM, Lucas PC. Hu D, et al. Nat Cancer. 2025 Jul;6(7):1202-1222. doi: 10.1038/s43018-025-00969-4. Epub 2025 Jun 27. Nat Cancer. 2025. PMID: 40579589
29,043 results
You have reached the last available page of results. Please see the User Guide for more information.